Pancreatic beta cells are critical in the regulation of glucose homeostasis by controlled secretion of insulin in mammals. Activation of PKA by cyclic AMP (cAMP) is shown to be responsible in enhancing this pathway, which is countered by phosphodiesterase (PDE) that converts cAMP to AMP and turns off the signal. Salt inducible kinases (SIKs) were also known to inhibit cAMPsignaling, mostly by promoting inhibitory phosphorylation on CREB regulated transcription coactivators (CRTCs). Here we showed that SIK1 regulates insulin secretion in beta cells by modulating PDE4D and cAMP concentrations. Haploinsufficiency of SIK1 led to the improved glucose tolerance due to the increased glucose-stimulated insulin secretion (GSIS). Depletion of SIK1 promoted higher cAMP concentration and increased insulin secretion from primary islets, suggesting that SIK1 controls insulin secretion through the regulation of cAMP signaling. By using a consensus phosphorylation site of SIK1, we identified PDE4D as a new substrate for this kinase family. In vitro kinase assay as well as mass spectrometry analysis revealed that the predicted Ser136 as well as the adjacent Ser141 of PDE4D are critical in SIK1-mediated phosphorylation. We found that either overexpression of SIK1 or PDE4D in beta cells reduced insulin secretion, while inhibition of PDE4 activity by rolipram or knockdown of PDE4D restored it, showing indeed that SIK1-dependent phosphorylation of PDE4D is critical in reducing cAMP concentration and insulin secretion from beta cells. Taken together, we propose that SIK1 serves as a part of self-regulatory circuit to modulate insulin secretion from pancreatic beta cells by controlling cAMP concentration through modulation of PDE4D activity.
INTRODUCTION
Glucose homeostasis is primarily regulated by the action of anabolic hormone insulin that is secreted from pancreatic beta cells. Impaired insulin secretion due to the beta cell dysfunction leads to the severe health problems in diabetic patients that are associated with hyperglycemiainitiated symptoms including ketoacidosis, cardiovascular diseases, and kidney failure (1) .
Factors that regulate insulin secretion from beta cells include various hormonal and nutritional components including glucose itself, intracellular concentration of Ca 2+ , ATP, diacylglycerol (DAG), inositol 1,4,5-trisphosphate (IP 3 ), and cyclic AMP (cAMP) (2) . cAMP signaling is shown to be critical in enhancing glucose-stimulated insulin secretion (GSIS) in beta cells.
Incretins such as glucagon like peptide 1 (GLP1) or gastric inhibitory peptide (GIP) could potentiate this process by activation of G protein coupled receptor-initiated increase in cAMP signaling in beta cells (3; 4) . In addition, glucose metabolism itself could control cAMP signaling, suggesting that incretin-independent activation of cAMP signaling by glucose could be also critical in insulin secretion and insulin granule exocytosis in pancreatic beta cells (2) .
In addition to its role in insulin secretion, cAMP signaling was also shown to be critical in the beta cell function by a transcriptional mechanism. A previous report showed that CREBdependent transcription is critical in the maintenance of beta cell mass by using RIP A-CREB transgenic mice, a beta cell specific transgenic mice expressing CREB inhibitor (5) . They showed that inhibition of CREB activity in beta cells resulted in the apoptosis primarily due to the lack of expression of insulin receptor substrate 2 (IRS2) and subsequent loss of the insulin signal transduction pathway in this cell type. The role of CREB co-activators such as CREB binding protein (CBP) and CREB regulated transcriptional coactivator 2 (CRTC2) were also shown to be critical in the maintenance of beta cell mass, accentuating the importance of cAMPdependent transcription pathway in the glucose homoeostasis via controlling the functions of pancreatic beta cells (6) (7) (8) .
Salt inducible kinases (SIKs), members of AMP activated protein kinase (AMPK) related kinases (AMPKRK), play critical roles in the regulation of cAMP-mediated transcription by enhancing inhibitory phosphorylation of CREB regulated transcriptional coactivators (CRTCs) and glucose homeostasis (9) (10) (11) . SIK1 is a founding member of SIK family of kinases that Ad-GFP, Ad-US (nonspecific RNA interference (RNAi) control), Ad-SIK1 and Ad-SIK1 RNA interference adenoviruses were described previously (13) . Adenovirus expressing Ad-SIK1
T182A, Ad-PDE4D, Ad-PDE4D mutants, Ad-PDE4D RNAi were generated by homologous recombination between adenovirus backbone vector pAD-Easy and linearized transfer vector pAD-Track as described previously (17) .
Cell culture and isolation of pancreatic islets
INS-1 cells were grown in RPMI 1640 medium (Gibco) supplemented with 10 % FBS, 11 mM glucose, 10 mM HEPES, 50 µM β-mercaptoethanol, 100 U/ml penicillin, and 100 µg/ml streptomycin as described (18) . Islets were isolated by collagenase (sigma) digestion of the WT, SIK1 +/-, SIK1 -/-and SIK2 -/-mouse pancreas. Pancreata were digested at 37 °C for 10 -15 min and islets were hand-picking on HBSS (Hank's Balanced Salt Solution). Islets were cultured in RPMI-1640 media supplemented with 10 % FBS, 11 mM glucose, 100 U/ml penicillin, and 100 µg/ml streptomycin overnight at 37 °C prior to experiment for recovery.
Insulin secretion
For insulin secretion, INS-1 cells or islets were pre-incubated for 2 hr in glucose free KrebsRinger bicarbonate buffer (KRBB), and then switched to KRBB with either 2.8 mM glucose or 16.7 mM glucose for 30 min unless otherwise noticed in the figure legends. Secreted insulin concentration in the media was determined by using an ELISA kit (Alpco, Salem, NH, USA) and was normalized to insulin contents.
Perifusion experiment
Dynamic insulin secretion in the perifusate was measured via an ultrasensitive enzyme immunoassay (Mercodia, Uppsala, Sweden) using an automated perifusion system. Briefly, a low-pulsatility peristaltic pump pushed KRPH buffer containing 0.2 % BSA and 2.8 mM glucose at a perifusion rate of 100 ml/min through a perifusion chamber (Biorep Technologies, Miami, FL) containing 100 pancreatic islets immobilized in Bio-Gel P-4 Gel (Bio-Rad, Hercules, CA).
After a 30 min stabilization period, the groups of islets were successively stimulated with 16.7 mM glucose. The perifusate was collected in an automatic fraction collector designed for a 96-well plate format. The perifusion chamber containing the islets were kept at 37 °C, and the 7 perifusate in the collecting plate was kept at <4 °C. The perifusate solutions were gassed with 95 % O 2 and 5 % CO 2 and maintained at 37 °C. Perifusates were collected every minute.
Measurement of membrane capacitance
Exocytosis was detected as changes in cell capacitance as described with a modification (19) .
Briefly, secretion was elicited by trains of nine 500-ms depolarizations (1-Hz stimulation frequency) from -70 mV to 0 mV. Patch electrodes were made from borosilicate glass capillaries (Clark Electromedical Instruments, Pangbourne, UK) using a puller (PP830; Narishige, Tokyo, Japan). The pipette resistance ranged between 2 and 4 MΩ when the pipettes were filled with the intracellular solutions specified below. The zero-current potential of the pipette was adjusted in the bath before giga-seal formation. We used a perforated whole-cell patch-clamp technique, in which the cells remain metabolically intact. All measurements were conducted using an EPC-10 patch-clamp amplifier (HEKA Electronics, Lambrecht/Pfalz, Germany) and Patchmaster software. The Normal Tyrode (NT) was used as the bathing solution, contained 123 mM NaCl, 
Western blot analysis
Western blot analyses of whole-cell extracts were performed as previously described (20) .
Antibodies for AKT, phospho-Ser473 AKT, CREB, and phospho-AMPK substrate antibody were from Cell Signaling Technology, antibodies for HA-HRP, flag-M2 were provided from Sigma-Aldrich, antibody for CRTC2 was from Calbiochem, antibody for phospho-Ser133 CREB was from Rockland, and antibody for PDE4D was from Proteintech. Antibodies to heat shock protein-90 (HSP90; Santa Cruz) or α-tubulin (Sigma-Aldrich) were used as loading controls.
Q-PCR
Total RNA from either cultured cells or tissues was extracted using RNeasy mini-kit (Qiagen).
cDNA generated by Superscript II enzyme (Invitrogen) was analyzed by Q-PCR using a SYBR green PCR kit and CFX Connect Real-Time System (BIO-RAD). All data were normalized to ribosomal L32 expression.
In Vitro kinase assays.
Induction and purification of GST fusion proteins in E. coli were performed by the manufacturer's protocol (Amersham Pharmacia Biotech). SIK1 protein was expressed by transfection in 293T cells and immunoprecipitated with anti-Flag agarose (Sigma) and then eluted using 3X Flag peptide. The kinase assay was performed using GST-fused substrates with the eluted SIK1 in the presence of 2.5 µCi ATP for 1 hr at 30 °C. Results were assessed by autoradiography (GE Healthcare) (21).
Mass Spectrometry analysis
For the analysis of phosphorylated serine/threonine residues on PDE4D, pcDNA3-Flag-SIK1
and pcDNA3-HA-PDE4D constructs were transiently transfected into 293T cells for 48 hr. HA-PDE4D was isolated by immunoprecipitation with anti-HA agarose and analyzed by SDS-PAGE gel. The protein band corresponding to PDE4D was excised and subjected to in-gel digestion with trypsin. Nano LC-Mass/Mass analysis was performed using LTQ ABI Q-STAR mass spectrometer (Agilent). The modified peptides were analyzed by using the mascot algorithm (Matrixscience). The experiment was performed in Yonsei Proteomics Research Center, Seoul, Korea.
RESULTS

Depletion of SIK1 leads to the increased insulin secretion from beta cells.
To delineate the metabolic function of SIK1 in vivo, we utilized a genetic mouse model for SIK1 deficiency. Mice homozygous for SIK1 null allele did not display embryonic lethality, but were born at less than the Mendelian ratio with a much smaller body weight ( Fig. 1A and Sup Since mice heterozygous for SIK1 were born in a normal Mendelian ratio and did not display any apparent growth phenotype, we utilized SIK1 heterozygous mice (SIK1 +/-) for most of our study. Interestingly, SIK1 +/-mice also showed lower blood glucose levels than their wild type (WT) littermate both under normal diet and high fat diet conditions, without changes in body weight or plasma triacylglycerol (TG) and non esterified fatty acid (NEFA) levels ( insulin levels were elevated in SIK1 +/-mice during the glucose tolerance test, suggesting indeed that depletion of SIK1 could promote increased insulin secretion from beta cells in vivo ( Fig. 1D and Sup Fig. 2D ). Subsequent insulin tolerance test revealed no difference between mice with two genotypes, showing that insulin response itself was not disturbed upon haploinsufficiency of SIK1 (Sup Fig. 2E and Sup Fig. 2F ). In line with the latter finding, we did not observe any changes in insulin signaling in insulin-sensitive tissues, as evidenced by the lack of changes in serine 473 phosphorylation level of Akt in the liver, muscle, or white adipose tissue (Sup Fig. 3A and Sup Fig. 3B ).
To corroborate the hypothesis that SIK1 deficiency may promote increased insulin secretion from beta cells, we utilized primary islet in culture that were prepared from either WT or SIK1 +/-mice. Indeed, we observed that the insulin secretion from SIK1 +/-islets was higher than those from WT islets, without changes in total insulin contents ( Fig. 2A) . Perifusion analysis also showed increased glucose-stimulated insulin secretion (GSIS) in SIK1 +/-islets compared with the control both in the 1 st phase and 2 nd phase of GSIS (Fig. 2B ). In addition, we also observed that the cAMP levels from SIK1 +/-islets were higher than those from WT islets (Fig. 2C ).
cAMP signaling was previously shown to be involved in the exocytosis of insulin granules. We presumed that the increased cAMP concentration in SIK1 +/-islets could also lead to the enhanced exocytosis of insulin granules from these cells. Thus, we measured the membrane capacitance of single beta cells from either WT or SIK1 +/-mice, and found that SIK1 +/-beta cells displayed significantly elevated secretory responses compared with that of the control (Fig.   2D ). These data collectively suggest that increased cAMP concentration upon SIK1 depletion in the beta cells could lead to the increased insulin secretion via the enhanced exocytosis of insulin granules.
PDE4D is an evolutionarily conserved phosphorylation target of SIK1.
Based on the presence of broader substrates for AMPK, a close paralogues of SIK kinases, we speculated that SIK1 could also have still unidentified substrates that might play roles in various signaling cascades including cAMP signaling. To this end, we used amino acids 164 to 176 from mouse CRTC2 to determine the consensus sequence for SIK1 substrates. We randomly substituted each amino acid except the serine 171 residue, a site that is phosphorylated by SIK1, and performed in vitro kinase assay. The assay revealed that SIK1-dependent phosphorylation requires the presence of hydrophobic residues (leucine, isoleucine, and valine) in the -5 and +4
positions relative to the phosphoacceptor serine residue (Fig. 3A) . In addition, the presence of basic residues (arginine, lysine) is preferred in the -3 position, in line with the original
as a consensus site of SIK1 and screened for the additional putative substrates. The motif search program identified candidate proteins that matched with the consensus sequences, and 56 candidates were subsequently selected that could be potentially relevant to the function of SIK1 (Sup Table 1 ). To confirm whether the selected proteins could serve as substrates for SIK1, GST-tagged peptides containing 13 amino acids from the candidates were generated and were subsequently tested by in vitro kinase assay. Among 56 candidates, 10 peptides were shown to be phosphorylated by SIK1 in vitro (Fig. 3B) , including proteins involved in the energy metabolism (p300, and AAKG3), cardiac muscle differentiation and maturation (SRF), cell cycle checkpoint (MLTK), or other cellular signaling cascades (PDE4D, TAB2, RAF1, JKIP, and BRAF), which were further confirmed through in vitro kinase assay by using truncated proteins (data not shown).
Among the candidates, p300 was shown to be phosphorylated by SIK2, a close paralogue of SIK1, in the liver, corroborating the usefulness of our approach (23).
We were particularly intrigued by the identification of PDE4D, a cAMP-specific phosphodiesterase among the candidates, since cAMP was known to be a negative regulator for SIKs through protein kinase A (PKA) in number of tissues. Consensus sequence surrounding serine 136 of PDE4D is conserved in other PDE4 isoforms (PDE4A-D), but not in other PDE isoforms (Fig. 3C, top) . Furthermore, we found that the conservation of predicted SIK consensus sites in PDE4D in Coelomata including Drosophila Melanogaster, suggesting that the circuitous regulation of cAMP and SIK could be conserved across eukaryotic organisms (Fig. 3C, bottom) .
Mass spectrometric analysis revealed that serine 136 of PDE4D is indeed highly phosphorylated in the cell. In addition, adjacent site (serine 141, also conserved in all PDE4 isoforms) of PDE4D
was also shown to be significantly phosphorylated, although the nature of the candidate kinase for this site was not ostensible (Fig. 3D ). Mutational analysis revealed that serine to alanine mutation on serine 136 in PDE4D completely ablated its SIK1-dependent phosphorylation, and serine 141 to alanine mutant PDE4D also affected SIK1-dependent phosphorylation levels in a lesser degree (Fig. 3E ). Double point mutations on both serine residues to alanine also completely abolished SIK1-dependent phosphorylation on PDE4D. Together with the mass spectrometry analysis, these data suggest that serine 141 might be either phosphorylated by SIK1 or could be required for the SIK1-mediated phosphorylation of PDE4D at the adjacent serine 136.
Indeed, these two sites were shown to be phosphorylated by previous study, corroborating the significance of our finding (24).
SIK1-dependent phosphorylation and activation of PDE4D reduces cAMP levels in beta cells.
Having seen the potential regulation of PDE4D by SIK1, we wanted to explore whether SIK1 could directly regulate cAMP signaling by controlling cAMP concentration in beta cells.
Expression of SIK1 was highly induced after 30 min treatment of forskolin (over 30-fold), picked at about 1 hr, and stayed elevated up to 4 hr in INS-1 beta cells (Fig. 4A, top) . mRNA levels of SIK2 were reduced in response to forskolin treatment, while SIK3 mRNA did not fluctuate during the course of forskolin treatment. Similarly, SIK1 protein level was also induced after 1 hr treatment of forskolin, peaked at 2 hr, and remained higher at 4 hr treatment of forskolin in INS-1 beta cell (Fig. 4A, bottom) . The induction of SIK1 by forskolin treatment was also shown in primary islets (Fig. 4B ). The induction of SIK1 expression by cAMP signaling was previously shown in hepatocytes and neuronal cells, suggesting that the similar mechanism is also conserved in beta cells (13; 15) . These data suggest that SIK1 could be potentially involved in the feedback inhibitory mechanism in reducing cAMP-dependent signaling at the later point after initial burst. In line with this idea, we observed the elevations of cAMP levels 1 -2 hr after the forskolin treatment, which were then reduced at 4 hr forskolin treatment in the control cells (Fig. 4C, left) . On the other hand, cAMP levels remained elevated during the course proteins, leading to the increased calcium influx and the subsequent increase in insulin secretion (25). Indeed, we observed a slight increase in SIK2 mRNA levels in SIK1 +/-pancreas as well as SIK1 +/-islets compared with the WT, potentially suggesting that depletion of SIK1 may induce SIK2 expression, causing the enhanced GSIS in islets (Sup Fig. 5A ). To verify this hypothesis, we tested the proven pan-SIK inhibitor (HG-9-91-01) in primary islets (26). Unlike the results from the previous report, the treatment of HG-9-91-01 led to the increased GSIS in WT islets.
HG-9-91-01 treatment led to a slight increase in GSIS in SIK1 +/-islets, and it did not affect the GSIS in SIK1 -/-islets, suggesting that the inhibition of SIK1 activity was crucial in HG-9-91-01-dependent enhancement of GSIS in islets (Sup Fig. 5B ). Indeed, the depletion of SIK1 did not affect SIK2 or p35 protein levels, showing that SIK1 did not regulate SIK2-p35-dependent pathway in primary islets in C57/BL6 background (Sup Fig. 5C ). To further exclude the possibility that the effect of SIK1-depletion on GSIS in beta cells could be due to the presence of SIK2, we infected adenovirus expressing shRNA for SIK2 in SIK1 +/-beta cells. Again, we observed an increase in GSIS from SIK1 +/-beta cells compared with the control. However, we did not observe any changes in GSIS from SIK1 +/-beta cells with up to 50 per cent knockdown of SIK2, showing indeed that SIK2 did not have a significant effect on GSIS in SIK1-depleted beta cells at least under the C57/BL6 background (Sup Fig. 5D ). In our hand, SIK2 was equally effective as SIK1 in inhibiting insulin secretion in INS-1 beta cells when ectopically expressed (Sup Fig. 5E ). Finally, we prepared primary islets from either WT mice or SIK2 knockout mice under the C57/BL6 background, and measured the GSIS. Unlike the result from the previous report, we observed a slight induction in insulin secretion from SIK2 -/-islets both under basal and high glucose concentrations (Sup Fig. 5F ). These data suggest that SIK2 might not be critically involved in insulin secretion from beta cells at least under the C57/BL6 background.
SIK1 controls cAMP-dependent insulin secretion through PDE4D-dependent pathway.
We found that serine 136 of PDE4D is a target of SIK1-mediated phosphorylation and the adjacent serine 141 could be also critical in this process. Since SIK1 overexpression decreased cAMP concentration while depletion of SIK1 increased it, we presumed that SIK1-mediated phosphorylation of PDE4 could enhance its activity toward the degradation of cAMP in beta cells. Thus, we generated adenovirus expressing serine to alanine mutants of PDE4D in a hope to generate PDE4D proteins with reduced activity. Expression of WT PDE4D indeed reduced cAMP concentration as well as GSIS significantly. A single point mutation of PDE4D (S136A or S141A) did not affect its activity greatly. However, a mutant PDE4D with both serine residues to alanine (S136/141A) displayed a drastically impaired ability in reducing both cAMP concentration and insulin secretion, showing that SIK1-dependent phosphorylation of PDE4D is critical in its ability to regulate cAMP concentration and subsequent insulin secretion in beta cells ( These data accentuate the specific roles of SIK family of kinases in the regulation of metabolic processes in various tissues.
We attempted to isolate potential phospho-targets of SIKs based on the in-silico approach using the consensus SIK-motif using the CRTC2 sequences. Interestingly, we identified ULK1
and BRAF as potential candidates for SIK1-dependent phospho-substrates, which were confirmed by in vitro kinase assay. Recent reports showed that both of these proteins are targets of AMPK, an important regulator of metabolic pathways as well as cellular proliferation (30; 31). It will be of interest to investigate whether SIKs and perhaps other members of AMPKRK could be also involved in the regulation of these proteins in the future. On a similar note, we could speculate that other identified targets of SIK1 in the current study might be also regulated by AMPK in certain conditions. Delineation of specific roles of AMPK and its related kinases in the regulation of various cellular signaling pathways warrants the further research.
By using a SIK consensus motif, followed by in vitro kinase assay, we identified PDE4D as a substrate for SIK family of kinases. By mass spectrometry, we discovered that the evolutionarily conserved serine 136 is a phospho-target of SIK1, and the adjacent serine 141 might be also critical in SIK1-meditated phosphorylation. Further investigation is necessary to clarify the role of serine 141 in the SIK1-dependent phosphorylation of the adjacent serine 136. The fact that Page 16 of 49 Diabetes serine 141 was also conserved among various species also suggests the importance of this amino acid in the proper regulation of PDE4D by SIK1. Serine 141 might be targeted by members of map kinases (MAPK) by a sequence prediction program, although the exact identity of a potential kinase should be elucidated by a further investigation.
While we were preparing this manuscript, a report by Sakamaki et al. suggested that SIK2 enhanced insulin secretion from the beta cells by promotion of p35 degradation (25). To explore the possibility that SIK1 could also control the insulin secretion via a p35-dependent pathway, we measured both SIK2 and p35 protein levels in SIK1-depleted primary islets. As shown in Sup   Fig. 5C , we did not observe any changes in either SIK2 or p35 protein levels, showing that SIK1 deficiency did not affect SIK2-p35-dependent pathway. The notion was further confirmed by the fact that knockdown of SIK2 did not affect the GSIS in SIK1 +/-beta cells (Sup Fig. 5D ).
Curiously, we observed an increase in the GSIS in SIK2 -/-islets compared with the control, while Sakamaki et al. showed a rather reduction in the GSIS in SIK2 -/-islets (Sup Fig. 5F, (25) ).
In addition, we were able to observe an increase in the GSIS by the treatment of pan-SIK inhibitor, HG-9-91-01, in primary islets, while the Screaton's group reported the opposite result (Sup Fig. 5B, (25) ). Several differences between their system and our system might account for the discrepancy. First, Sakamaki et al. used pancreas specific-temporal Cre system to knockout SIK2 (1-2-week post tamoxifen injection), while we used systemic, chronic SIK2 KO models.
Although, we would expect to observe a similar effect on GSIS upon SIK2 depletion in the isolated islets, we cannot completely exclude the possibility that chronic SIK2-depletion might affect the beta cell properties. We did not observe a significant differences in the insulin content between WT islets and SIK2 -/-islets. Second, we used C57/BL6 background for our SIK1 or SIK2 KO mice (SIK1 mice were generated by using C57/BL6 albino ES cells and were backcrossed for 10 generations once we obtained the SIK1 +/-mice; we purchased SIK2 +/-mice under the C57/BL6/129SV background and backcrossed them for 10 generations), while Screaton et al. used mice under the FVB background (16; 25) . Finally, we directly obtained HG-9-91-01 from the original investigator who developed and tested the reagent (Dr. Nathanael Gray), unlike Screaton et al., who obtained the chemical from the indirect sources. Further study is necessary whether the genetic background or a slight differences in chemicals indeed affected the discrepancy. As least in our system, we could safely conclude that the effect of SIK1 depletion on GSIS is not through SIK2-p35-dependent pathway.
In this report, we found that haploinsufficiency of SIK1 in mice led to the lower blood glucose levels with improved glucose tolerance when challenged with high fat diet. Insulin secretion from SIK1 +/-islets was enhanced compared with the wild type control, due in part to the elevation in cAMP concentration. Conversely, overexpression of SIK1 reduced cAMP concentration and insulin secretion from the beta cells, and this effect was largely blunted by either the treatment of PDE4 inhibitor or PDE4D knockdown. Expression of wild type PDE4D, but not S136/141A mutant PDE4D, reduced cAMP concentration and insulin secretion, showing indeed that SIK1-dependent phosphorylation of PDE4D is critical in the regulation of cAMPdependent signaling pathway in beta cells. It is noteworthy to state that cAMP signaling and PKA suppress SIK1 activity by inhibitory phosphorylation at its serine 577 residue (32) . We and data in (B) and (D) represent mean ± SEM (*;P < 0.05, **;P < 0.01, ***;P < 0.001, t-test). GST  WT  L166I  N167R  R168Y  T169A  S170R  D172H  S173V  A174V  L175I  H176V  GST  WT  L166V  N167K  R168G  T169F  S170E  D172W  S173N  A174L  L175F  H176A   GST  WT  L166IA  N167H  R168F  T169S  S170F  D172G  S173T  A174S  L175V  H176I  GST  WT  L166T  N167G  R168A  T169P  S170L  D172A  S173A  A174Q  L175R  H176G   GST  WT  L166K  N167P  R168K  T169R  S170Q  D172S  S173L  A174T  L175K  H176F  GST  WT  L166N  N167D  R168H  T169L  S170A  D172L  S173E  A174W  L175M  H176Y   GST  WT  L166G  N167V  R168T  T169V  S170C  D172N  S173D  A174I  L175G  H176S  GST  WT  L166E  N167Q  R168L  T169K  S170G  D172P  S173Q  A174R  L175Q  H176R   P represent mean ± SD (*;P < 0.05, **;P < 0.01, ***;P < 0.001, t-test). 
